HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

OT-82

NAMPT inhibitor

Also Known As:

3-(2-(4-Fluorophenyl)ethynyl)-N-(3-(1H-pyrazol-4-yl)propyl)-4-pyridin-4-ylbenzamide

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gudkov, Andrei V: 2 articles (01/2020 - 01/2020)
2.	Gupta, Mahima: 2 articles (01/2020 - 01/2020)
3.	Haber, Michelle: 2 articles (01/2020 - 01/2020)
4.	Henderson, Michelle J: 2 articles (01/2020 - 01/2020)
5.	Korotchkina, Lioubov: 2 articles (01/2020 - 01/2020)
6.	Lock, Richard B: 2 articles (01/2020 - 01/2020)
7.	Middlemiss, Shiloh: 2 articles (01/2020 - 01/2020)
8.	Norris, Murray D: 2 articles (01/2020 - 01/2020)
9.	Somers, Klaartje: 2 articles (01/2020 - 01/2020)
10.	Collins, Victor J: 1 article (09/2020)

Related Diseases

1.	Leukemia 01/01/2020 - "OT-82 was well-tolerated and demonstrated impressive single agent in vivo efficacy, achieving significant leukemia growth delay in 95% (20/21) and disease regression in 86% (18/21) of PDXs. " 01/01/2020 - "Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. "
2.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2020 - "These results reveal strong dependence of neoplastic cells of hematopoietic origin on NAMPT and introduce OT-82 as a promising candidate for the treatment of hematological malignancies." 01/01/2020 - "OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis." 01/01/2020 - "Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. "
3.	Multiple Myeloma 01/01/2020 - "Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. "
4.	Acute Erythroblastic Leukemia (Erythroleukemia) 01/01/2020 - "Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. "
5.	Burkitt Lymphoma (Burkitt's Lymphoma) 01/01/2020 - "Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. "

Related Drugs and Biologics

1.	NAD (NADH)
2.	Nicotinamide Phosphoribosyltransferase